{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:48:11Z","timestamp":1767134891102,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd006682.pub5","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T00:00:00Z","timestamp":1567641600000}}],"reference-count":78,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006682.pub6","type":"journal-article","created":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T13:11:38Z","timestamp":1567689098000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Duration of intravenous antibiotic therapy in people with cystic fibrosis"],"prefix":"10.1002","volume":"2019","author":[{"given":"Linsey","family":"Abbott","sequence":"first","affiliation":[{"name":"Northern General Hospital; Pharmacy Department; Herries Road Sheffield UK S5 7AU"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Plummer","sequence":"additional","affiliation":[{"name":"Northern General Hospital; Pharmacy Department; Herries Road Sheffield UK S5 7AU"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe Hui","family":"Hoo","sequence":"additional","affiliation":[{"name":"University of Sheffield; Medical Statistics Group, ScHARR; Regent Court, 30 Regent Street Sheffield UK S1 4DA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Wildman","sequence":"additional","affiliation":[{"name":"Northern General Hospital; Adult Cystic Fibrosis Unit; Herries Road Sheffield UK S5 7AU"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,9,5]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD006682.pub6-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jcf.2010.09.003","article-title":"Twice vs three-times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis","volume":"10","author":"Adeboyeku","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD006682.pub6-BIB0002|cit2","first-page":"294","article-title":"Meropenem (MEM) compared with ceftazidime (CAZ) in combination with tobramycin (TOB) for treatment of acute pulmonary exacerbations (APE) in patients with cystic fibrosis (CF) infected with Pseudomonas aeruginosa (PA) or burkholderia cepacia (BC) [abstract]","volume":"Suppl 25","author":"Blumer","year":"2003","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD006682.pub6-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1378\/chest.128.4.2336","article-title":"The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis","volume":"128","author":"Blumer","year":"2005","journal-title":"Chest"},{"issue":"18","key":"10.1002\/14651858.CD006682.pub6-BIB0004|cit4","first-page":"1614","article-title":"Intravenous administration of antibiotics at home in patients with cystic fibrosis improves quality of life","volume":"85","author":"Hjelte","year":"1988","journal-title":"Lakartidningen"},{"issue":"9","key":"10.1002\/14651858.CD006682.pub6-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1128\/AAC.00174-09","article-title":"Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis","volume":"53","author":"Hubert","year":"2009","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1002\/14651858.CD006682.pub6-BIB0006|cit6","first-page":"294","article-title":"Continuous infusion versus intermittent administration of ceftazidime in cystic fibrosis patients [abstract]","volume":"Suppl 25","author":"Hubert","year":"2003","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD006682.pub6-BIB0007|cit7","unstructured":"NCT00333385 Continuous versus short infusions of ceftazidime in cystic fibrosis https:\/\/clinicaltrials.gov\/show\/NCT00333385 2006"},{"key":"10.1002\/14651858.CD006682.pub6-BIB0008|cit8","unstructured":"Kapranov NI Belousov YB Kashyrskaya NY Smirnova EY Quinoline therapy in children with cystic fibrosis [abstract] Proceedings of 20th European Cystic Fibrosis Conference; 1995 June 18-21; Brussels, Belgium 1995 P19"},{"issue":"7","key":"10.1002\/14651858.CD006682.pub6-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1128\/AAC.01797-10","article-title":"Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis","volume":"55","author":"Keel","year":"2011","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006682.pub6-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"S39, Abstract n","DOI":"10.1016\/S1569-1993(09)60158-2","article-title":"Eradication of Pseudomonas aeruginosa in adults with CF [abstract]","volume":"8","author":"Kenny","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD006682.pub6-BIB0011|cit11","unstructured":"Knight RK Batten JC Mearns M A double blind trial of cephalexin in cystic fibrosis patients with pseudomonas in the sputum [abstract] Proceedings of 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands 1979 52"},{"issue":"2","key":"10.1002\/14651858.CD006682.pub6-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jcf.2007.07.001","article-title":"Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis","volume":"7","author":"Latzin","year":"2008","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD006682.pub6-BIB0013|cit13","unstructured":"EUCTR 2009-014042-28-GB What duration of intravenous antibiotic therapy should be used in the treatment of infective exacerbations of cystic fibrosis in patients chronically colonised with Pseudomonas aeruginosa? - Duration of antibiotics in infective exacerbations of cystic fibrosis www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2009-014042-28-GB"},{"key":"10.1002\/14651858.CD006682.pub6-BIB0014|cit14","unstructured":"NCT01044719 Duration of antibiotics in infective exacerbations of cystic fibrosis clinicaltrials.gov\/ct2\/show\/NCT01044719"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006682.pub6-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S1569-1993(07)60126-X","article-title":"A prospective trial on the efficacy and tolerability of twice-daily dosing (TDD) versus once-daily dosing (ODD) amikacin in cystic fibrosis patients [abstract]","volume":"6","author":"Postnikov","year":"2007","journal-title":"Journal of Cystic Fibrosis"},{"issue":"5","key":"10.1002\/14651858.CD006682.pub6-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s15010-009-8117-4","article-title":"Tobramycin once- vs thrice-daily for elective intravenous antipseudomonal therapy in pediatric cystic fibrosis patients","volume":"37","author":"Riethmueller","year":"2009","journal-title":"Infection"},{"key":"10.1002\/14651858.CD006682.pub6-BIB0017|cit17","unstructured":"Riethmueller J Busch A Franke P Ziebach R von Butler R Stern M Pharmacodynamic variation of intravenous antibiotic treatment with ceftazidime and tobramycin in CF-patients is equally effective [abstract] Proceedings of 13th international cystic fibrosis congress; 2000 June 4-8; Stockholm, Sweden 2000 166"},{"key":"10.1002\/14651858.CD006682.pub6-BIB0018|cit18","unstructured":"Riethmueller J Franke P Schroeter TW Claass A Busch A Ziebach R Optimised intravenous antibiotic treatment with ceftazidime (thrice daily vs continuous) and tobramycin (thrice vs once daily) in CF patients [abstract] Proceedings of 24th European cystic fibrosis conference; 2001 June 6-9; Vienna, Austria 2001 P192"},{"issue":"5","key":"10.1002\/14651858.CD006682.pub6-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s15010-009-8116-5","article-title":"Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis","volume":"37","author":"Riethmueller","year":"2009","journal-title":"Infection"},{"key":"10.1002\/14651858.CD006682.pub6-BIB0020|cit20","first-page":"289","article-title":"Acute-phase nephrotoxicity of tobramycin in CF patients: A prospective randomized trial of once-versus thrice-daily dosing [abstract]","volume":"Suppl 24","author":"Schroeter","year":"2002","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD006682.pub6-BIB0021|cit21","unstructured":"Schroeter TW Eggert P Riethmueller J Stern M Claass A A prospective randomized trial on the nephrotoxicity of thrice-daily versus once-daily tobramycin in cystic fibrosis patients [abstract] Proceedings of 24th European cystic fibrosis conference; 2001 June 6-9; Vienna, Austria 2001 P190"},{"key":"10.1002\/14651858.CD006682.pub6-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"S55, Abstract n","DOI":"10.1016\/S1569-1993(10)60215-9","article-title":"Efficiency of the inhalational tobramycin therapy in complex antibacterial therapy of lung exacerbation in cystic fibrosis children with chronic pseudomonas aeruginosa infection [abstract]","volume":"9 Supplement 1","author":"Semykin","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"issue":"5","key":"10.1002\/14651858.CD006682.pub6-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jcf.2017.04.003","article-title":"Standardized Treatment of Pulmonary Exacerbations (STOP) study: physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary exacerbations.","volume":"16","author":"West","year":"2017","journal-title":"J Cyst Fibros"},{"key":"10.1002\/14651858.CD006682.pub6-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/S1569-1993(18)30390-4","article-title":"Design, enrolment, and feasibility of the STOP-2 randomised study of intravenous antibiotic treatment duration in cystic fibrosis pulmonary exacerbations","volume":"17 Suppl 3","author":"Flume","year":"2018","journal-title":"Journal of Cystic Fibrosis"},{"issue":"Suppl 47","key":"10.1002\/14651858.CD006682.pub6-BIB0025|cit25","first-page":"388","article-title":"Design, enrollment, and feasibility of the STOP-2 randomised study of iv antibiotic duration in CF pulmonary exacerbations","volume":"52","author":"Heltshe","year":"2017","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD006682.pub6-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cct.2017.11.012","article-title":"Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): a trial to compare intravenous antibiotic treatment durations in CF","volume":"64","author":"Heltshe","year":"2018","journal-title":"Contemporary Clinical Trials"},{"key":"10.1002\/14651858.CD006682.pub6-BIB0027|cit27","unstructured":"NCT02781610 Standardized treatment of pulmonary exacerbations II (STOP2) clinicaltrials.gov\/ct2\/show\/NCT02781610"},{"issue":"S2","key":"10.1002\/14651858.CD006682.pub6-BIB0028|cit28","first-page":"324","article-title":"Update on the STOP-2 randomized study of IV antibiotic duration in CF pulmonary exacerbations","volume":"53","author":"Sanders","year":"2018","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 47","key":"10.1002\/14651858.CD006682.pub6-BIB0029|cit29","first-page":"124","article-title":"Treatment of pulmonary exacerbations","volume":"52","author":"West","year":"2017","journal-title":"Pediatric pulmonology"},{"issue":"3","key":"10.1002\/14651858.CD006682.pub6-BIB0030|cit30","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001917.pub2","article-title":"Home intravenous antibiotics for cystic fibrosis","author":"Balaguer","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006682.pub6-BIB0031|cit31","unstructured":"British Thoracic Society British Thoracic Society guidelines for the management of non-tuberculosis mycobacterial pulmonary disease (NTM-PD) Thorax November 2017"},{"key":"10.1002\/14651858.CD006682.pub6-BIB0032|cit32","unstructured":"Cystic Fibrosis Foundation Microbiology and Infectious disease in cystic fibrosis Consensus Conference, Bethesda 1994 1 26"},{"key":"10.1002\/14651858.CD006682.pub6-BIB0033|cit33","unstructured":"Cystic Fibrosis Foundation National Patient Registry Annual Data Report 2000 [Bethesda, Maryland] 2001"},{"key":"10.1002\/14651858.CD006682.pub6-BIB0034|cit34","unstructured":"UK Cystic Fibrosis Trust Antibiotic Group Antibiotic treatment for Cystic Fibrosis Report of the UK Cystic Fibrosis Trust Antibiotic Group 2009"},{"issue":"9041","key":"10.1002\/14651858.CD006682.pub6-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/S0140-6736(05)66225-3","article-title":"Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic","volume":"348","author":"Cheng","year":"1996","journal-title":"Lancet"},{"issue":"8","key":"10.1002\/14651858.CD006682.pub6-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/0895-4356(94)00230-N","article-title":"Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection","volume":"48","author":"Demko","year":"1995","journal-title":"Journal of Clinical Epidemiology"},{"issue":"6","key":"10.1002\/14651858.CD006682.pub6-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/00063198-200311000-00007","article-title":"Update on pathogenesis of cystic fibrosis lung disease","volume":"9","author":"Donaldson","year":"2003","journal-title":"Current Opinion in Pulmonary Medicine"},{"issue":"4","key":"10.1002\/14651858.CD006682.pub6-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1034\/j.1399-3003.2000.16d30.x","article-title":"Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus","volume":"16","author":"Doring","year":"2000","journal-title":"European Respiratory Journal"},{"issue":"6","key":"10.1002\/14651858.CD006682.pub6-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jcf.2012.10.004","article-title":"Treatment\u00a0of\u00a0lung\u00a0infection\u00a0in\u00a0patients\u00a0with\u00a0cystic fibrosis:\u00a0current\u00a0and\u00a0future\u00a0strategies","volume":"11","author":"D\u00f6ring","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"issue":"1","key":"10.1002\/14651858.CD006682.pub6-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jcf.2003.12.007","article-title":"Genotyping of Pseudomonas aeruginosa in cystic fibrosis suggests need for segregation","volume":"3","author":"Edenborough","year":"2004","journal-title":"Journal of Cystic Fibrosis"},{"issue":"11","key":"10.1002\/14651858.CD006682.pub6-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1136\/thx.2003.017285","article-title":"Difficult bacteria, antibiotic resistance and transmissibility in cystic fibrosis","volume":"59","author":"Elborn","year":"2004","journal-title":"Thorax"},{"issue":"1","key":"10.1002\/14651858.CD006682.pub6-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD006682.pub6-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ppul.10127","article-title":"Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis","volume":"34","author":"Emerson","year":"2002","journal-title":"Pediatric Pulmonology"},{"issue":"12","key":"10.1002\/14651858.CD006682.pub6-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1038\/s41431-018-0234-z","article-title":"Estimating the age of p.(Phe508del) with family studies of geographically distinct European populations and the early spread of cystic fibrosis","volume":"26","author":"Farrell","year":"2018","journal-title":"European Journal of Human Genetics"},{"issue":"9","key":"10.1002\/14651858.CD006682.pub6-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1164\/rccm.200812-1845PP","article-title":"Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations","volume":"180","author":"Flume","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"5 Pt 1","key":"10.1002\/14651858.CD006682.pub6-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1164\/ajrccm.160.5.9805046","article-title":"Burkholderia cepacia in cystic fibrosis: variable disease course","volume":"160","author":"Frangolias","year":"1999","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"8","key":"10.1002\/14651858.CD006682.pub6-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1164\/rccm.200304-505SO","article-title":"Pathophysiology and management of pulmonary infections in cystic fibrosis","volume":"168","author":"Gibson","year":"2003","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD006682.pub6-BIB0048|cit48","first-page":"93","article-title":"Microbiology of CF Lung Disease","volume-title":"Cystic Fibrosis in Adults","author":"Gilligan","year":"1999"},{"issue":"6","key":"10.1002\/14651858.CD006682.pub6-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jcf.2008.06.009","article-title":"Early aggressive eradication therapy for intermittent Pseudomonas Aeruginosa airway colonisation in cystic fibrosis patients: 15 years experience","volume":"7","author":"Hansen","year":"2008","journal-title":"Journal of Cystic Fibrosis"},{"issue":"18","key":"10.1002\/14651858.CD006682.pub6-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"5395","DOI":"10.1128\/JB.183.18.5395-5401.2001","article-title":"Alginate overproduction affects Pseudomonas aeruginosa biofilm structure and function","volume":"183","author":"Hentzer","year":"2001","journal-title":"Journal of Bacteriology"},{"issue":"7414","key":"10.1002\/14651858.CD006682.pub6-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006682.pub6-BIB0052|cit52","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration 2011. Available from www.cochrane-handbook.org"},{"issue":"6","key":"10.1002\/14651858.CD006682.pub6-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1159\/000056287","article-title":"Treatment of cystic fibrosis in the adult","volume":"67","author":"Hodson","year":"2000","journal-title":"Respiration"},{"issue":"4","key":"10.1002\/14651858.CD006682.pub6-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1159\/000079640","article-title":"Isolation of fungi, especially Exophiala dermatitidis, in patients suffering from cystic fibrosis. A prospective study","volume":"71","author":"Horre","year":"2004","journal-title":"Respiration"},{"issue":"6","key":"10.1002\/14651858.CD006682.pub6-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2165\/00128072-200002060-00004","article-title":"Prospects for the prevention and control of pseudomonal infection in children with cystic fibrosis","volume":"2","author":"H\u00f8iby","year":"2000","journal-title":"Paediatric Drugs"},{"issue":"9281","key":"10.1002\/14651858.CD006682.pub6-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0140-6736(01)05714-2","article-title":"Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic","volume":"358","author":"Jones","year":"2001","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD006682.pub6-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/thorax.57.11.924","article-title":"Increased treatment requirements of patients with cystic fibrosis who harbour a highly transmissible strain of Pseudomonas aeruginosa","volume":"57","author":"Jones","year":"2002","journal-title":"Thorax"},{"issue":"2","key":"10.1002\/14651858.CD006682.pub6-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jcf.2017.11.019","article-title":"Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: a longitudinal study using UK patient registry data","volume":"17","author":"Keogh","year":"2018","journal-title":"Journal of Cystic Fibrosis"},{"issue":"Suppl 7","key":"10.1002\/14651858.CD006682.pub6-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"S608","DOI":"10.1093\/clinids\/13.Supplement_7.S608","article-title":"Retrospective clinical study of hypersensitivity reactions to astreonam and six other beta-lactam antibiotics in cystic fibrosis patients receiving multiple antibiotic courses","volume":"13","author":"Koch","year":"1991","journal-title":"Reviews of Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD006682.pub6-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000087686","article-title":"Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa","volume":"73","author":"Lechtzin","year":"2006","journal-title":"Respiration"},{"issue":"12","key":"10.1002\/14651858.CD006682.pub6-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/ppul.20517","article-title":"Viral and atypical bacterial infections in the outpatient pediatric cystic fibrosis clinic","volume":"41","author":"Olesen","year":"2006","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD006682.pub6-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1378\/chest.11-0917","article-title":"Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa","volume":"141","author":"Parkins","year":"2012","journal-title":"Chest"},{"issue":"6","key":"10.1002\/14651858.CD006682.pub6-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/thx.2004.027953","article-title":"Antibiotic allergy in cystic fibrosis","volume":"60","author":"Parmar","year":"2005","journal-title":"Thorax"},{"issue":"7","key":"10.1002\/14651858.CD006682.pub6-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/thx.42.7.526","article-title":"Cystic fibrosis in adolescents and adults","volume":"42","author":"Penketh","year":"1987","journal-title":"Thorax"},{"issue":"5","key":"10.1002\/14651858.CD006682.pub6-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1651-2227.1981.tb05757.x","article-title":"Respiratory infections in cystic fibrosis patients caused by virus, chlamydia and mycoplasma - possible synergism with Pseudomonas aeruginosa","volume":"70","author":"Petersen","year":"1981","journal-title":"Acta Paediatrica Scandinavica"},{"issue":"5","key":"10.1002\/14651858.CD006682.pub6-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/ppul.20023","article-title":"Pulmonary exacerbation in cystic fibrosis","volume":"37","author":"Rabin","year":"2004","journal-title":"Pediatric Pulmonology"},{"issue":"3","key":"10.1002\/14651858.CD006682.pub6-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1056\/NEJM199607183350307","article-title":"Management of pulmonary disease in patients with cystic fibrosis","volume":"335","author":"Ramsey","year":"1996","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD006682.pub6-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/ppul.10100","article-title":"Predictors of deterioration of lung function in cystic fibrosis","volume":"33","author":"Schaedel","year":"2002","journal-title":"Pediatric Pulmonology"},{"issue":"11","key":"10.1002\/14651858.CD006682.pub6-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"816","DOI":"10.7326\/0003-4819-143-11-200512060-00010","article-title":"Pathogenesis of early lung disease in cystic fibrosis: A window of opportunity to eradicate bacteria","volume":"143","author":"Starner","year":"2005","journal-title":"Annals of Internal Medicine"},{"issue":"8","key":"10.1002\/14651858.CD006682.pub6-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S2213-2600(18)30266-2","article-title":"Disadvantages of set length antibiotic treatment for pulmonary exacerbation","volume":"6","author":"Stephen","year":"2018","journal-title":"Lancet Respiratory Medicine"},{"issue":"3","key":"10.1002\/14651858.CD006682.pub6-BIB0071|cit71","first-page":"117","article-title":"Early eradication of Pseudomonas aeruginosa in patients with cystic fibrosis. Review article","volume":"11","author":"Stuart","year":"2010","journal-title":"Peadiatric Respiratory Reviews"},{"key":"10.1002\/14651858.CD006682.pub6-BIB0072|cit72","unstructured":"UK Cystic Fibrosis Trust Cystic Fibrosis strength in numbers UK Cystic Fibrosis Reigistry Annual Data Report 2017 www.cysticfibrosis.org.uk\/\u02dc\/media\/documents\/the-work-we-do\/uk-cf-registry\/2017-registry-annual-data-report-interactive.ashx?la=en 2018"},{"issue":"6","key":"10.1002\/14651858.CD006682.pub6-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jcf.2016.04.005","article-title":"Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis.","volume":"15","author":"VanDevanter","year":"2016","journal-title":"J Cyst Fibros"},{"issue":"930","key":"10.1002\/14651858.CD006682.pub6-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/pmj.79.930.201","article-title":"Impact of respiratory viral infections on cystic fibrosis","volume":"79","author":"Wat","year":"2003","journal-title":"Postgraduate Medical Journal"},{"issue":"6","key":"10.1002\/14651858.CD006682.pub6-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jcf.2015.07.010","article-title":"Prolongation of antibiotic treatment for cystic fibrosis pulmonary exacerbations","volume":"14","author":"Waters","year":"2015","journal-title":"J. Cyst Fibros"},{"issue":"1","key":"10.1002\/14651858.CD006682.pub6-BIB0076|cit76","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006682.pub3","article-title":"Duration of intravenous antibiotic therapy in people with cystic fibrosis","author":"Plummer","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD006682.pub6-BIB0077|cit77","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006682.pub4","article-title":"Duration of intravenous antibiotic therapy in people with cystic fibrosis","author":"Plummer","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD006682.pub6-BIB0078|cit78","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006682.pub5","article-title":"Duration of intravenous antibiotic therapy in people with cystic fibrosis","author":"Plummer","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD006682.pub6\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,26]],"date-time":"2021-12-26T04:46:55Z","timestamp":1640494015000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006682.pub6"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,9,5]]},"references-count":78,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006682.pub6","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,5]]}}}